Published in Thromb J on November 16, 2011
Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. J Biol Chem (2012) 0.88
Hemostatic matrix effects on blood loss after total knee arthroplasty: A randomized controlled trial. Indian J Orthop (2013) 0.84
Incidence of venous thromboembolism and hemorrhage related safety studies of preoperative anticoagulation therapy in hip fracture patients undergoing surgical treatment: a case-control study. BMC Musculoskelet Disord (2016) 0.83
Venous thromboembolism following major orthopedic surgery. Maedica (Buchar) (2013) 0.77
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes. World J Orthop (2014) 0.75
Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA Atheroscler (2014) 0.75
Can patients with femoral neck fracture benefit from preoperative thromboprophylaxis?: A prospective randomized controlled trial. Medicine (Baltimore) (2017) 0.75
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med (2010) 4.77
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med (1998) 2.58
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med (1996) 2.55
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16
Prevention of fatal postoperative thromboembolism by heparin prophylaxis. Lancet (1970) 2.12
Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ (1991) 1.94
Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost (2005) 1.80
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb Haemost (1997) 1.73
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Prevention of postoperative venous thromboembolism. Br J Anaesth (1995) 1.64
Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br (2006) 1.56
Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med (1999) 1.50
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med (2000) 1.48
Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand (2000) 1.42
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest (2003) 1.36
Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res (2002) 1.15
Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost (2007) 1.09
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest (2003) 1.08
Vessel injury, platelet adherence, and platelet survival. Arteriosclerosis (1984) 1.04
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost (2007) 1.00
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res (1998) 0.95
Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty. Thromb Res (2010) 0.95
The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis. Clin Appl Thromb Hemost (2009) 0.94
Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med (1995) 0.92
Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy (2000) 0.92
Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. Am J Manag Care (2010) 0.91
Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res (1991) 0.90
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg (1986) 0.90
The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coagul Fibrinolysis (1995) 0.87
Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res (2001) 0.87
Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry. Thromb Haemost (2008) 0.85
Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen. Clin Appl Thromb Hemost (2009) 0.82
Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thromb Res (2010) 0.81
Risk factors for venous thromboembolism in orthopedic surgery. Isr Med Assoc J (2002) 0.79
Hypercoagulability: introduction and perspective. Semin Thromb Hemost (1990) 0.77
Applying risk assessment models in orthopaedic surgery: effective risk stratification. Blood Coagul Fibrinolysis (1999) 0.76